Entera Bio's EB613 Abstracts For Osteoporosis Treatment Accepted For WCO-IOF-ESCEO Congress From April 10-13, 2025; Phase 2 Shows Rapid BMD Increase, Enhanced Bone Formation, Resorption Suppression

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of oral peptide and protein replacement therapies in tablet form, today announced that the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) Scientific Programme Committee has accepted both submitted abstracts related to EB613 for presentation at the WCO-IOF-ESCEO congress. The congress will take place at the Roma Convention Center, Rome, Italy from April 10 to April 13, 2025.

EB613 is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34) tablet treatment to support earlier osteoanabolic intervention, for high-risk post-menopausal women with osteoporosis. In a Placebo-controlled Phase 2 study, 6 months of EB613 treatment demonstrated fast onset of action and robust increases in BMD at all skeletal sites. Further, EB613 induced increases in bone formation (P1NP) and suppression of bone resorption (CTX).